menu
    • menu
    [{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SD-101","moa":"Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ TriSalus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"DNA","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Oligodeoxynucleotide","moa":"Toll-like-9 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SD-101","moa":"Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"ImaginAb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ TriSalus Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"MedTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Merger","leadProduct":"Nelitolimod","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ MedTech","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ MedTech"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||TLR9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intrahepatic Arterial Infusion","sponsorNew":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"TriSalus Life Sciences \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"SD-101","moa":"Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Hepatic Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SD-101","moa":"Toll-like receptor 9 (TLR9)","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nelitolimod","moa":"TLR9","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"TriSalus Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Calcium Folinate","moa":"Proton-coupled folate transporter; Dihydrofolate reductase","graph1":"Oncology","graph2":"Phase I","graph3":"TriSalus Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ TriSalus Life Sciences","highestDevelopmentStatusID":"6","companyTruncated":"TriSalus Life Sciences \/ TriSalus Life Sciences"},{"orgOrder":0,"company":"TriSalus Life Sciences","sponsor":"Dynavax Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Nelitolimod","moa":"TLR9","graph1":"Oncology","graph2":"Undisclosed","graph3":"TriSalus Life Sciences","amount2":0.26000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.26000000000000001,"dosageForm":"Undisclosed","sponsorNew":"TriSalus Life Sciences \/ TriSalus Life Sciences","highestDevelopmentStatusID":"1","companyTruncated":"TriSalus Life Sciences \/ TriSalus Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by TriSalus Life Sciences

    Menu

    TriSalus Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SD-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 29, 2024

                            Lead Product(s) : SD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : University of California, San Diego

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Gets WHO Approval for “Nelitolimod” Nonproprietary Name

                            Details : TriSalus SD-101 (Nelitolimod), a TLR-9 agonist, is in phase 1 trials for treating uveal melanoma with liver metastases, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Nelitolimod

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Dat...

                            Details : SD-101, the Company’s investigational TLR9 agonist, is being delivered via TriNav® to selected sites, including tumors in the liver. It has the potential to reprogram and eliminate MDSCs.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 16, 2023

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progr...

                            Details : SD-101, the company’s investigational TLR9 agonist, is being delivered via TriNav® to selected sites, including tumors in the liver. SD-101, a class C toll-like receptor 9 (“TLR9”) agonist.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

                            Details : Under the agreement, ImaginAb will license and supply clinical doses of investigational CD8 ImmunoPET to TriSalus for use in its clinical trials using its proprietary Pressure-Enabled Drug Delivery method for intravascular delivery of its investigational...

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            November 22, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : ImaginAb

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 C...

                            Details : The promising clinical data demonstrate that SD-101 delivered via TriNav® may support broad immune effects in liver tumors and eliminate myeloid-derived suppressor cells (“MDSC”).

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 21, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MedTech

                            Deal Size : $110.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation

                            Details : TriSalus is developing SD-101, a class C toll-like receptor 9 (TLR9) agonist, that promotes T Cell infiltration, reduction of myeloid derived suppressor cells (MDSC) and broad immune activation to reverse immunosuppression in the liver and pancreas.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : $110.0 million

                            November 14, 2022

                            Lead Product(s) : Nelitolimod,Nivolumab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MedTech

                            Deal Size : $110.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SD-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic A...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 07, 2022

                            Lead Product(s) : SD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelitolimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via P...

                            Details : SD-101, a potentially first-in-class, investigative TLR9 agonist, to reactivate the immune system within the liver and pancreas to enable more durable responses to other immunotherapeutics (e.g., checkpoint inhibitors) and improve patient outcomes.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 05, 2022

                            Lead Product(s) : Nelitolimod,Ipilimumab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : The University of Texas MD Anderson Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed

                            TriSalus Life Sciences

                            U.S.A arrow
                            CPhI Korea
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SD-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 02, 2022

                            Lead Product(s) : SD-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth